Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493445 | 0.86 | SIGMAR1 (0.49) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL22490275 | 0.78 | ADRB2 (0.56) | SLC2A1ADRB2ADRB3 | |
| SCHEMBL22493833 | 0.77 | SIGMAR1 (0.54) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL22493353 | 0.76 | HTT (0.56) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL22493477 | 0.74 | SIGMAR1 (0.51) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL19505478 | 0.71 | SIGMAR1 (0.84) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL4019777 | 0.71 | SIGMAR1 (0.84) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL3621767 | 0.71 | SIGMAR1 (0.84) | MEN1KMT2ASIGMAR1SLC2A1HTT | |
| SCHEMBL19498794 | 0.70 | SIGMAR1 (0.89) | MEN1KMT2ASIGMAR1HTTSMN1; SMN2 | |
| SCHEMBL22493455 | 0.70 | SIGMAR1 (0.46) | MEN1KMT2ASIGMAR1SLC2A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2020198466-A9 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | MEN1 4299/4885KMT2A 4289/4885SIGMAR1 71/4885 |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | MEN1 3795/4885KMT2A 983/4885SIGMAR1 170/4885 |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | MEN1 3795/4885KMT2A 983/4885SIGMAR1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.